公开(公告)号：US20100160328A1

公开(公告)日：2010-06-24

申请号：US12637354

申请日：2009-12-14

申请人： Peter Aranyi ,  Imre BATA ,  Sandor Batori ,  Eva BORONKAY ,  Philippe BOVY ,  Zoltan Kapui ,  Edit SUSAN ,  Tibor SZABO ,  Katalin Urban-Szabo ,  Marton VARGA

发明人： Peter Aranyi ,  Imre BATA ,  Sandor Batori ,  Eva BORONKAY ,  Philippe BOVY ,  Zoltan Kapui ,  Edit SUSAN ,  Tibor SZABO ,  Katalin Urban-Szabo ,  Marton VARGA

IPC分类号： A61K31/53 ,  C07D403/12 ,  A61K31/506 ,  C07D207/46 ,  A61K31/40 ,  C07D253/065 ,  A61P3/10 ,  A61P3/04 ,  A61P25/24 ,  A61P25/18 ,  A61P35/00 ,  A61P9/04

CPC分类号： C04B35/632 ,  C07D207/16 ,  C07D213/74 ,  C07D215/38 ,  C07D221/22 ,  C07D231/38 ,  C07D241/20 ,  C07D253/06 ,  C07D261/14 ,  C07D277/42 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D451/02 ,  C07D471/04

摘要： The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their preparation and intermediates of the general formulae (II), (IV), (V), (VII), (VIII) and (IX).

摘要翻译： 本发明涉及具有二肽基肽酶IV酶抑制活性的通式（I）的新化合物，其药物组合物，使用所述化合物的方法，其制备方法和通式（II），（IV）的中间体） ，（V），（VII），（VIII）和（IX）。

公开(公告)号：US20070021459A1

公开(公告)日：2007-01-25

申请号：US11425583

申请日：2006-06-21

申请人： Michel ALETRU ,  Peter ARANYI ,  Maria BALOGH ,  Sandor BATORI ,  Judit BENCE ,  Philippe BOVY ,  Zoltan KAPUI ,  Endre MIKUS ,  Claudie NAMANE ,  Christophe PHILIPPO ,  Tibor SZABO ,  Zsuzsanna TOMOSKOZI ,  Katalin URBAN-SZABO

发明人： Michel ALETRU ,  Peter ARANYI ,  Maria BALOGH ,  Sandor BATORI ,  Judit BENCE ,  Philippe BOVY ,  Zoltan KAPUI ,  Endre MIKUS ,  Claudie NAMANE ,  Christophe PHILIPPO ,  Tibor SZABO ,  Zsuzsanna TOMOSKOZI ,  Katalin URBAN-SZABO

IPC分类号： A61K31/4709 ,  A61K31/4439 ,  A61K31/415 ,  C07D403/14 ,  C07D403/02 ,  C07D231/14

CPC分类号： C07D409/04 ,  C07D231/16 ,  C07D231/56 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14

摘要： The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.

摘要翻译： 本发明涉及食欲素受体拮抗剂通式（I）化合物及其异构体，盐和溶剂合物，其含有它们的药物组合物及其治疗应用。

公开(公告)号：US20070015745A1

公开(公告)日：2007-01-18

申请号：US11464537

申请日：2006-08-15

申请人： Philippe BOVY ,  Roberto CECCHI ,  Gilles COURTEMANCHE ,  Tiziano CROCI ,  Ambrogio OLIVA ,  Nunzia VIVIANI

发明人： Philippe BOVY ,  Roberto CECCHI ,  Gilles COURTEMANCHE ,  Tiziano CROCI ,  Ambrogio OLIVA ,  Nunzia VIVIANI

IPC分类号： A61K31/553 ,  A61K31/538 ,  A61K31/423 ,  A61K31/138 ,  C07D263/52

CPC分类号： C07C311/21 ,  C07C229/46 ,  C07C311/08 ,  C07C317/22 ,  C07C2601/14

摘要： The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an —S(O)z(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —SO2NH(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl group or an —NHSO2phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C1-C4)alkyl group or with a (C1-C4)alkoxy group; R1 represents a hydrogen atom or a (C1-C4)alkyl group, a —CO(C1-C4)alkyl group, a phenyl-(C1-C4)alkyl group or a —CO—phenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C1-C4)alkoxy group; R2 is a hydrogen atom or an —SO2(C1-C4)alkyl group, an —SO2phenyl-(C1-C4)alkyl group or an —SO2phenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C1-C4)alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; R3 represents a hydrogen or halogen atom, a (C1-C6)alkyl group, a (C1-C4)alkoxy group, a —COO(C1-C4)alkyl group, a —CO(C1-C4)alkyl group, an —NHSO2(C1-C4)alkyl group, an —NHSO2phenyl-(C1-C4)alkyl groups, —NO2, —CN, —CONR4R5, —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; R4 and R5 represent, independently, a hydrogen atom, a phenyl, a (C1-C4)alkyl group or a phenyl-(C1-C4)alkyl group or R4 and R5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.